CPR Investments’s Moderna MRNA Stock Holding History

CPR Investments’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,475	Closed	-$211K	–	43
2022 Q2	$211K	Buy	1,475 +42	+3%	+$6K	0.32%	43
2022 Q1	$247K	Buy	1,433 +319	+29%	+$53.7K	0.2%	69
2021 Q4	$283K	Buy	+1,114	New	+$326K	0.2%	60

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPR Investments's MRNA Position: Q3 2022 in Review

CPR Investments sold out of Moderna (MRNA) in Q3 2022, closing a stake of 1,475 shares — an estimated $211K sold.

CPR Investments first reported a position in MRNA in Q4 2021 and held it in 3 quarters. The position peaked at $283K in Q4 2021. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

CPR Investments reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
CPR Investments sold 1,475 Moderna shares in Q3 2022, an estimated $211K.
CPR Investments first reported a position in Moderna in Q4 2021 and held it in 3 quarters.
CPR Investments's Moderna position peaked at $283K in Q4 2021.
915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on CPR Investments's 13F filing for Q3 2022, filed 14 Nov 2022.